Huntington's disease (HD) is an inherited progressive neurodegenerative disorder resulting from CAG repeat expansion in the gene that encodes for the protein huntingtin. To identify neuroprotective compound (s) that can slow down disease progression and can be administered long term with few side effects in Huntington's disease, we investigated the effect of sertraline, a selective serotonin reuptake inhibitor (SSRI) which has been shown to upregulate BDNF levels in rodent brains. We report here that in HD mice sertraline increased BDNF levels, preserved chaperone protein HSP70 and Bcl-2 levels in brains, attenuated the progression of brain atrophy and behavioral abnormalities and thereby increased survival. Sertraline also enhanced neurogenesis, which appeared to be responsible for mediating the beneficial effects of sertraline in HD mice. Additionally, the effective levels of sertraline are comparable to the safe levels achievable in humans. The findings suggest that sertraline is a potential candidate for treatment of HD patients.
Introduction
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder in which neurons in the striatum and the cerebral cortex degenerate, resulting in abnormal involuntary movements (chorea), and psychiatric and cognitive abnormalities (Reiner et al., 1998; Vonsattel et al., 1985; Myers et al., 1988) . Death usually occurs within 10-20 years after onset of the first clinical symptoms. Although the mechanism of neuronal degeneration in HD is unclear, it is thought that disease onset and progression may be involved in transcription dysregulation (Cha, 2003; Sugars and Rubinsztein, 2003) and deficits of neurotrophic factors (Zuccato et al., 2001 (Zuccato et al., , 2005 Zuccato and Cattaneo, 2007; Ferrigno and Silver, 2000; Gauthier et al., 2004; Cowan and Raymond, 2006) , with cumulative neuronal loss.
It has been demonstrated that levels of brain-derived neurotrophic factor (BDNF) are decreased in brain cells of HD patients and mutant huntingtin transgenic mice. Although the crucial mechanism(s) of neuronal death induced by mutant htt is still unclear, mutant huntingtin promotes neuronal degeneration, in part by suppressing BDNF transcription and/or blocking axonal transport of BDNF from cerebral cortex to striatum (Zuccato et al., 2001 (Zuccato et al., , 2003 Gauthier et al., 2004) . Other studies have shown that BDNF can protect neurons against insults relevant to the pathogenesis of HD (Bemelmans et al., 1999; Kells et al., 2004; Canals et al., 2004; Cepeda et al., 2004; Pineda et al., 2005; Zuccato et al., 2005; Lynch et al., 2007) . In addition to promoting neuronal survival, BDNF also regulates neurogenesis (Duman, 2004; Cotman and Berchtold 2002) . Altered neurogenesis occurred in mouse models of HD and in postmortem brains in humans with the disease (Phillips et al., 2006 (Phillips et al., , 2005 Grote et al., 2005; Gil et al., 2005; Tattersfield et al., 2004; Lazic et al., 2004; Curtis et al., 2003) . Mutant huntingtin also interrupts other cellprotective systems, such as chaperone protein, leading to dysfunction of the protein refolding system (Landles and Bates 2004).
There is currently no therapy to delay onset or prevent disease progression in HD patients. Promising approaches have been reported in preclinical trials, such as treating with FGF-2 (Jin et al., 2005) and GDNF (McBride et al., 2006) , which prevented neuronal death and dysfunction, or by replacing lost neurons by transplanting embryonic stem cells (Conti et al 2006) . Nonetheless, most of these approaches are associated with ethical, technical, and immunological problems for application to human patients (Rosser and Dunnett, 2003) . Searching for drugs that can delay onset and/or slow disease 
